Repligen (NASDAQ:RGEN) Shares Gap Up – Here’s Why

Repligen Co. (NASDAQ:RGEN) gapped up prior to trading on Tuesday . The stock had previously closed at $139.51, but opened at $147.50. Repligen shares last traded at $149.99, with a volume of 93,024 shares trading hands.

Analyst Ratings Changes

Several equities analysts recently issued reports on RGEN shares. UBS Group decreased their price target on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Wells Fargo & Company initiated coverage on Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. Finally, Benchmark reissued a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Repligen Stock Up 6.9 %

The firm has a market cap of $8.35 billion, a PE ratio of -3,751.75, a PEG ratio of 4.04 and a beta of 0.96. The stock has a fifty day moving average price of $141.34 and a 200-day moving average price of $144.87. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Repligen

Several hedge funds have recently bought and sold shares of the business. Cerity Partners LLC raised its stake in shares of Repligen by 90.0% during the 3rd quarter. Cerity Partners LLC now owns 5,541 shares of the biotechnology company’s stock worth $825,000 after purchasing an additional 2,625 shares in the last quarter. Nicolet Advisory Services LLC grew its holdings in Repligen by 6.6% in the 3rd quarter. Nicolet Advisory Services LLC now owns 3,254 shares of the biotechnology company’s stock valued at $452,000 after buying an additional 201 shares during the last quarter. Champlain Investment Partners LLC grew its holdings in shares of Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after purchasing an additional 850,345 shares in the last quarter. Icon Wealth Advisors LLC grew its holdings in shares of Repligen by 2,081.6% during the 3rd quarter. Icon Wealth Advisors LLC now owns 32,571 shares of the biotechnology company’s stock worth $4,847,000 after purchasing an additional 31,078 shares in the last quarter. Finally, Raymond James Trust N.A. boosted its stake in Repligen by 20.9% in the 3rd quarter. Raymond James Trust N.A. now owns 2,750 shares of the biotechnology company’s stock valued at $409,000 after buying an additional 475 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.